Results 141 to 150 of about 54,207 (313)
Aging Cell, EarlyView.Therapeutic plasma exchange safely reduces biological age by up to 2.6 years. Multi‐omics analysis reveals coordinated cellular and molecular responses associated with aging rejuvenation. ABSTRACT We conducted a randomized, placebo‐controlled trial to assess the safety and biological age (BA) effects of various therapeutic plasma exchange (TPE ...
Matias Fuentealba +14 more
wiley +1 more source
Journal of Pharmacological Sciences, 2022 Although the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia is known to cause vascular adverse events (VAEs), the frequency of VAEs during dasatinib administration is not high, and the same holds for atherosclerosis ...
Masamitsu Takaba +5 more
doaj
Aging Cell, EarlyView.In male patients undergoing CABG surgery, pretreatment with quercetin suppressed inflammaging and its associated inflammation, leading to improved endothelium‐dependent relaxation (measured ex vivo) and reducing new onset of post‐operative atrial fibrillation.
Pauline Mury +19 more
wiley +1 more source
Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy
Case Reports in Cardiology, 2018 Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved as a first-line therapy for chronic myelocytic leukemia (CML). A 24-year-old man presenting dyspnea at rest and leg edema was admitted to our hospital.
Makoto Nishimori +8 more
doaj +1 more source
Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report
BMC Nephrology, 2019 Background Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib. Case presentation
Shoko Ochiai +4 more
doaj +1 more source
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer [PDF]
, 2017 SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease.
El-Helali, Aya +6 more
core +2 more sources
Aging Cell, EarlyView.Supplementation with the natural senolytic agent fisetin attenuated age‐related declines in physical function in mice. Better physical function with fisetin was accompanied by lower expression of cell senescence‐related genes. Fisetin treatment had comparable effects on physical function as genetic clearance of senescent cells and synthetic senolytic ...
Kevin O. Murray +10 more
wiley +1 more source
Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
Hematology Reports, 2017 A 69-year-old man with chronic-phase chronic myeloid leukemia was initially treated with 100 mg dasatinib once a day. Despite a major molecular response within 9 months, he developed hemorrhagic colitis 32 months after starting dasatinib.
Aya Nakaya +11 more
doaj +1 more source
Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer [PDF]
, 2008 Elevated c-Src protein expression has been shown in breast cancer and <i>in vitro</i> evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total
BS Verbeek +36 more
core +3 more sources
Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus
Aging Cell, EarlyView.In cohorts of lean controls, obese participants without Type 2 Diabetes Mellitus (T2DM) and obese T2DM participants, we find that T‐cell expression of senescence biomarkers is altered only in the T2DM participants and not with obesity alone. Moreover, high T‐cell p16 expression in the T2DM participants is associated with impaired bone cortical indices.
Caroline Hoong +9 more
wiley +1 more source